FY2027 Earnings Estimate for RXRX Issued By Leerink Partnrs

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Analysts at Leerink Partnrs issued their FY2027 earnings estimates for shares of Recursion Pharmaceuticals in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar forecasts that the company will earn ($0.84) per share for the year. The consensus estimate for Recursion Pharmaceuticals' current full-year earnings is ($1.57) per share.

Other equities analysts also recently issued reports about the stock. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Finally, Morgan Stanley lowered their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, Recursion Pharmaceuticals has a consensus rating of "Hold" and an average price target of $8.20.

Recursion Pharmaceuticals Stock Up 3.4 %

RXRX traded up $0.18 during trading hours on Friday, hitting $5.50. 12,710,040 shares of the company's stock were exchanged, compared to its average volume of 12,073,362. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -3.59 and a beta of 1.00. Recursion Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $12.36. The stock's 50-day moving average is $6.62 and its two-hundred day moving average is $6.80. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same quarter last year, the firm earned ($0.42) earnings per share. The business's revenue for the quarter was down 57.8% on a year-over-year basis.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. San Luis Wealth Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the first quarter worth $54,000. QRG Capital Management Inc. increased its holdings in Recursion Pharmaceuticals by 8.5% in the 1st quarter. QRG Capital Management Inc. now owns 28,515 shares of the company's stock valued at $151,000 after buying an additional 2,244 shares during the period. Mason & Associates Inc bought a new position in Recursion Pharmaceuticals in the 1st quarter valued at about $175,000. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Recursion Pharmaceuticals by 27.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 24,230 shares of the company's stock worth $128,000 after acquiring an additional 5,278 shares during the period. Finally, Azzad Asset Management Inc. ADV boosted its position in shares of Recursion Pharmaceuticals by 21.6% during the 1st quarter. Azzad Asset Management Inc. ADV now owns 16,811 shares of the company's stock worth $89,000 after acquiring an additional 2,982 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.